MediWound (NASDAQ:MDWD) Lowered to "Sell" Rating by Wall Street Zen

Wall Street Zen downgraded shares of MediWound (NASDAQ:MDWD - Free Report) from a hold rating to a sell rating in a research report released on Friday morning.

Several other analysts have also issued reports on MDWD. HC Wainwright set a $31.00 price objective on MediWound and gave the stock a "buy" rating in a report on Thursday, May 22nd. Alliance Global Partners began coverage on MediWound in a report on Friday, May 2nd. They set a "buy" rating and a $25.00 price objective for the company. Finally, Oppenheimer began coverage on MediWound in a report on Monday, June 2nd. They set an "outperform" rating and a $34.00 target price on the stock. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $32.25.

MediWound Stock Up 2.1%

Shares of MDWD traded up $0.42 during mid-day trading on Friday, reaching $20.49. The company's stock had a trading volume of 94,205 shares, compared to its average volume of 63,900. The business has a fifty day moving average of $20.28 and a 200 day moving average of $18.50. The company has a market cap of $221.50 million, a price-to-earnings ratio of -9.80 and a beta of 0.32. MediWound has a 1 year low of $14.14 and a 1 year high of $22.51.

MediWound (NASDAQ:MDWD - Get Free Report) last released its earnings results on Wednesday, May 21st. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.65) by $0.58. The company had revenue of $3.96 million during the quarter, compared to analyst estimates of $5.20 million. MediWound had a negative return on equity of 74.12% and a negative net margin of 110.45%. During the same quarter in the prior year, the company earned ($1.05) earnings per share. On average, analysts predict that MediWound will post -2.66 earnings per share for the current year.

Institutional Investors Weigh In On MediWound

Several hedge funds and other institutional investors have recently made changes to their positions in MDWD. Geode Capital Management LLC grew its position in shares of MediWound by 3.6% in the fourth quarter. Geode Capital Management LLC now owns 98,710 shares of the biopharmaceutical company's stock valued at $1,757,000 after purchasing an additional 3,408 shares during the last quarter. Russell Investments Group Ltd. grew its position in MediWound by 154.1% during the fourth quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 1,162 shares in the last quarter. Barclays PLC grew its position in MediWound by 11.2% during the fourth quarter. Barclays PLC now owns 12,412 shares of the biopharmaceutical company's stock worth $221,000 after buying an additional 1,249 shares in the last quarter. MGO One Seven LLC acquired a new stake in MediWound during the fourth quarter worth about $216,000. Finally, Northern Trust Corp grew its position in MediWound by 94.6% during the fourth quarter. Northern Trust Corp now owns 144,768 shares of the biopharmaceutical company's stock worth $2,577,000 after buying an additional 70,367 shares in the last quarter. 46.83% of the stock is owned by institutional investors and hedge funds.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.